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Objectives: Very few studies systematically investigated the differences in anti-
hypertensive pharmacotherapy in ambulatory care settings among different racial 
groups. The objectives of the study include: 1) To compare antihypertensive pre-
scription patterns by patient race in US ambulatory settings; 2) To determine fac-
tors affecting the recipient of each class of anti-antihypertensive regimen specific 
to racial groups. MethOds: All patient-physician encounters with primary diag-
nosis indicating essential hypertension (ICD-9 codes “401.0”, “401.1” and “401.9”) 
and patient age 18 years and older from National Ambulatory Medical Care Survey 
(NAMCS) for the years 2006-2010 were analyzed. Weighted univariate and bivariate 
analyses were performed to examine demographics and clinical characteristics 
in general and between the racial/ethnic groups. Multivariate logistic regression 
models were performed to investigate the adjusted likelihood of receiving each class 
of antihypertensive regimens by different racial groups, controlling for potential 
confounders. Results: A total of 12,674 visits were identified. The unadjusted pre-
scription rates by race (African Americans vs. Caucasians) were 23.1% vs. 20.3% (diu-
retics), 21.9% vs. 29.5% (BBs), 21.2% vs. 26.5% (ACEIs), 18.5% vs. 16.7% (CCBs), 14.5% 
vs. 14.8% (Angiotensin II Receptor Blockers, ARBs), 6.6% vs. 5.9% (Antiadrenergic 
agents), and 47.2% vs. 45.2% (combination regimens). Weighted logistic regression 
analyses determined that African Americans were more likely to receive diuret-
ics (OR= 1.396, P< .0001), Calcium Channel Blockers (BBs) (OR= 1.409, P< 0.0001), 
Anti-Adrenergic-agents (OR= 1.267, P= 0.0275), fixed-dose combinations (OR= 1.273, 
P= 0.0027), and multiple-pill-regimens (OR= 1.184, P= 0.0048) and less likely to receive 
ACEIs ( OR= 0.836, P= 0.0080), BBs (OR= 0.73, P< 0.0001) than Caucasians. Factors affect-
ing the likelihood of receiving different classes of antihypertensive agents include 
patient age, gender, co-morbid conditions, insurance-status, and health education 
profile. cOnclusiOns: In US Ambulatory Care Settings, African American patients 
receive systematically different antihypertensive regimens than their Caucasian 
counterparts. Further studies are needed to disentangle the potential effects from 
health insurance and utilization patterns on the racial variations in antihyperten-
sive pharmacotherapy.
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Objectives: Assess statin dosing patterns and lipid levels among UK high-risk 
vascular disease (HRVD) patients. MethOds: Patients with HRVD, including 
acute coronary syndrome (ACS), cerebrovascular arterial disease, peripheral arte-
rial disease, and diabetes with coronary artery disease (CAD), 4/1/2008–3/31/2011, 
were identified from the Clinical Practice Research Datalink with Hospital Episode 
Statistics data. Statin doses were assessed from the first prescription on/after the 
index date (date of diagnosis of cerebrovascular, peripheral, or CAD or 30 days after 
ACS hospital discharge). Use of high-intensity statin therapy (atorvastatin 40–80 mg 
or rosuvastatin 20–40 mg) was examined. Across 2 years of follow-up, upward-dose 
titration was noted. Lipid levels were examined for high-intensity and non-high-
intensity statin users and non-users. Results: Of 63,549 statin users with HRVD 
and ≥ 6 months’ follow-up, most (69.6%) received simvastatin; also prescribed were 
atorvastatin (23.3%), pravastatin (3.6%), rosuvastatin (3.2%), and fluvastatin (0.4%). 
The most frequent initial drug-dose combinations were simvastatin 40 mg (48.5%) 
and 20 mg (15.5%) and atorvastatin 40 mg (8.2%) and 80 mg (5.4%). Upward-dose 
titrations occurred in 8.9% of patients in 2 years. High-intensity statin use across 2 
years was 16.4% overall and highest in ACS (28.9%) relative to other HRVD conditions 
(range 8.8%–20.9%). Among patients with ≥ 1 low-density lipoprotein cholesterol 
(LDL-C) record in 2 years, 41.3%, 35.5%, and 5.3% of patients on high-intensity, non-
high-intensity, and no statin had LDL-C < 1.8 mmol/L. Similar patterns were seen 
with total cholesterol, but high-density lipoprotein cholesterol (HDL-C) > 1.2 mmol/L 
was observed in 46.3%, 54.9%, and 66.1% of high-intensity users, non-high-intensity 
users, and non-users, respectively. cOnclusiOns: Simvastatin 20–40 mg or atorv-
astatin 40–80 mg were most frequently prescribed for HRVD patients. Upward-dose 
titration was seldom seen. Statin use, especially at high intensity, was associated 
with lower LDL-C, although statin use was not associated with higher HDL-C.
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Objectives: Examine lipid-altering drug use patterns, statin adherence, and 
persistence among patients with high-risk vascular disease (HRVD) in the United 
Kingdom (UK). MethOds: Patients with HRVD, including a history of acute coronary 
syndrome (ACS; > 30 days–365 days after discharge for ACS), cerebrovascular arte-
rial disease, peripheral arterial disease, or diabetes with coronary artery disease, 
4/1/200–3/31/2011, with a minimum of 12-month continuous enrollment before 
the index date were identified using the Clinical Practice Research Datalink with 
Hospital Episode Statistics data. The date of the first HRVD diagnosis satisfying the 
above inclusion criteria was defined as the index date. Use of lipid-altering drugs 
was measured during the 6-, 12-, and 24-month follow-up periods. Statin adher-
ence (medication possession ratio [MPR]), was obtained for 6, 12, and 24 months 
after the index date. Statin persistence was estimated as the time from earliest 
statin use on or after the index date until the last date of exposure prior to a gap of 
≥ 30 days. Results: Of 119,267 HRVD patients with ≥ 6-month follow-up, 59.8% of 
patients used statin monotherapy, 3.3% used statin combination therapy (i.e., statin 
plus ezetimibe, niacin, fibrates, or bile acid sequestrants), and 35.3% had no recorded 
lipid-altering therapy. The usage patterns of statins and other lipid-altering drugs 
changed little during the rest of the 24-month follow-up period. The mean/median 
MPR during the 6-, 12-, and 24-month follow-up periods was 0.88/0.97, 0.85/0.96, and 
0.82/0.94, respectively, among HRVD patients who used a statin with 76.9%, 74.8%, 
and 71.3% of patients adherent (MPR≥ 80%) to their statin therapy. Median time to 
discontinuation of the index statin was 523 days during the 24-month follow-up 
period. cOnclusiOns: Close to two-thirds of HRVD patients used statin or other 
lipid-altering drugs during the 24-month follow-up period. Statin adherence and 
persistence were high among patients with HRVD in the UK.
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Objectives: Treatment with Angiotensin converting enzyme (ACE) inhibitors or 
angiotensin receptor blockers (ARBs) forms the first line of therapy in hypertensive 
diabetic patients. This study examined the factors associated with prescribing of 
ACE inhibitors/ARBs in nationally representative outpatient visits by hypertensive 
diabetic patients. MethOds: The 2010 National Ambulatory Medical Care Survey 
(NAMCS) and outpatient department of National Hospital Ambulatory Medical Care 
Survey (NHAMCS) database were used to conduct a retrospective cross-sectional 
study on visits by hypertensive diabetic patients (age ≥ 18 years). Bivariate chi square 
analysis and multivariable logistic regression were performed to evaluate the fac-
tors associated with prescribing of ACE inhibitors/ARBs. Results: A total of 59.47 
million outpatient visits were made by diabetic patients in 2010. Of these, 42% visits 
were made by patients with both diabetes and hypertension. Controlled blood pres-
sure (≤ 130/ 80 mmHg) was found in 44% (95% Cl: 39-47) of the total hypertensive 
diabetic visits. ACE inhibitors/ARBs were prescribed in 51% or 12.28 million (95% Cl: 
8.9- 15.61) hypertensive diabetic visits. Enalapril and Lisinopril were the most pre-
scribed ACE inhibitors; Losartan and Valsartan were the most prescribed ARBs. After 
controlling for various factors, multivariable logistic regression analysis showed 
that males were more likely to be prescribed ACE inhibitors/ARBs as compared to 
females (Odds Ratio, OR 1.63, 95% Cl: 1.01-2.62). Patients living in the Northeast were 
more likely to receive ACE inhibitors/ARBs as compared to those in the Midwest (OR 
2.67, 95% Cl: 1.40-5.13). cOnclusiOns: Hypertension management was suboptimal 
among hypertensive diabetic patients. Recommended first line of treatment, ACE 
inhibitors/ARBs were prescribed in over half of the outpatient visits. The study also 
found variation in use of ACE inhibitors/ARBs across gender and region. Future 
studies should examine factors related to gender disparities and regional variation 
in use of ACE inhibitors/ARBs in hypertensive diabetic patients.
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Objectives: Diseases of the heart pose an extreme burden on health care resources 
in the United States. Inpatient admissions originating from the emergency room 
increase the burden on health care resources and may be indicative of dispari-
ties in access to care. This study looked at the effect of patient characteristics on 
the source of inpatient admission for 3 types of heart surgeries. MethOds: This 
study used data from the 2011 Medical Expenditure Panel Survey. Logistic regres-
sion models were used to estimate associations between patient characteristics 
and source of inpatient admissions for coronary-artery bypass, pacemaker implant 
and valve surgeries. The models were adjusted for comorbidities and the level of 
significance was set at 95% CI. Results: There were 24 and 57 patients undergoing 
coronary-artery bypass and pacemaker implant surgeries, respectively. Of these 11 
coronary-artery bypasses and 12 pacemaker implants were admissions originating 
from the emergency room. No valve surgeries originated from the emergency room. 
Male patients of age 55 to 70 years with middle school education and having no 
insurance had higher odds for having an inpatient admission originating from the 
emergency room for coronary-artery bypass surgery (OR 1.23, CI 0.70- 0.85; OR: 1.56, 
CI 1.12-2.19; OR 5.91, CI 1.32-26.32; OR 1.30, CI 0.64-0.77), when compared with those 
with elective admissions for the procedure. The effects were similar for non-elective 
pacemaker implants. cOnclusiOns: Literature suggests that there are associa-
tions between non-elective surgical events and inpatient admissions through the 
emergency room. This study found that patient characteristics have an influence 
on the source of admission for inpatient heart surgeries. The demographic profile of 
patients at risk for heart surgeries originating from the emergency room is sugges-
tive of existent disparities in terms of age, education, gender and insurance status 
in the population sample. More research should explore whether this translates 
into other health care services.
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Objectives: In the United States, patients presenting to physicians’ offices with 
chest pain and related symptoms frequently undergo extensive non-invasive and 
